Purpose: To retrospectively evaluate the clinical, imaging, and pathologic findings of mammary angiosarcomas in 24 patients. Materials and Methods: The institutional review board approved this HIPAA-compliant study and waived informed consent. Twenty-four patients with records in the surgical pathology database who had a diagnosis of mammary angiosarcoma (n = 26) and who underwent preoperative imaging with mammography, ultrasonography (US), or magnetic resonance (MR) imaging were included. Mean and median ages at time of diagnosis were 40 and 38 years, respectively (range, 15–77 years). Images were reviewed in consensus by two radiologists with the American College of Radiology Breast Imaging Reporting and Data System lexicon and were compared with pathologic findings. Total length of follow-up (in months) was determined by the interval from the time of diagnosis to the time of last follow-up. Information on overall and disease-free survival was also obtained. Results: Mean tumor size at time of diagnosis...

For patients with large operable and locally advanced breast cancer, primary systemic chemotherapy (PST) is currently the standard of care. Primary systemic chemotherapy has been shown to be equivalent to adjuvant chemotherapy in terms of overall survival (OS) and relapse-free survival (RFS),^1,2 and use of PST also increases the rates of breast conservation surgery. Primary systemic chemotherapy has an additional advantage in that it allows response to be assessed clinically in vivo throughout treatment and pathologically after surgery. Several studies have shown that patients treated with PST who achieve a pathologic complete response (pCR) in the breast and axilla have superior long-term outcomes.^2-4

To retrospectively evaluate the imaging findings of breast lymphomas in patients who had undergone mammography, ultrasonography (US), magnetic resonance (MR) imaging, or combined positron emission tomography (PET)/computed tomography (CT) scanning. The institutional review board approved this HIPAA-compliant study and waived informed consent. Twenty-seven women who had been diagnosed with breast lymphoma (32 tumors) and had undergone preoperative imaging were identified from the surgical pathology database (mean age, 51 years; median, 55 years; range, 19-78 years at time of diagnosis). Two radiologists reviewed the mammographic, US, and MR images. One nuclear medicine physician reviewed the PET/CT scans. All available pathologic specimens were reviewed by a hematologic pathologist. The mean tumor size at diagnosis was 2.9 cm (range, 1-5 cm). Seventeen tumors manifested with a palpable mass, two with diffuse enlargement of the breast, and 13 were asymptomatic. Twenty-two women underwent mammography; 24, US; one, MR imaging; and 10, PET/CT scanning. Mammograms of 25 tumors showed a noncalcified mass in 19, global asymmetry in four, focal asymmetry in one, and no abnormality in one. US of 29 tumors showed a mass in 26 and diffuse architectural distortion in three. Masses typically were irregular, hypoechoic, and hypervascular and demonstrated indistinct margins or an echogenic boundary. Dynamic contrast material-enhanced MR imaging of one tumor showed an intensely and heterogeneously enhancing mass with rapid enhancement and washout characteristics. PET/CT scans of 13 tumors showed intense diffuse hypermetabolism in 12 and response to therapy in all 12 tumors. The imaging findings reported in this study should alert the radiologist to a possible diagnosis of breast lymphoma.